CD34; nonmalignant disease
Allogeneic stem cell transplantation offers the only hope of cure for a variety of nonmalignant diseases, 1 yet a number of serious side effects inhibit the use of this therapy for such patients. The toxicity of myeloablative conditioning can cause lethal complications. 2 Other complications include failure of engraftment; 3 susceptibility to infection because of delayed immune reconstitution 4, 5 or immunosuppressive graft-versus-host disease (GvHD) prophylaxis; and acute and chronic GvHD. 6 Among patients receiving bone marrow from HLA-identical siblings, approximately 35% experience grade II-IV GvHD, and approximately 15%, grade III-IV GvHD with an increased incidence in recipients of bone marrow from matched unrelated donors. 7 The incidence and severity of GvHD is higher with HLA incompatibility. 8, 9 Patients who receive a graft from an HLA-haploidentical family member with no detectable HLA-A, -B, or -DR disparity have an approximately 50% risk of grade II-IV GvHD, while those mismatched at one, two, or three loci have an estimated risk of 75, 78, and 80%, respectively. 10 In patients with malignant diseases, the mortality caused by GvHD may be counterbalanced by a graft-versus-tumor effect 11 that reduces the incidence of relapse. 12 In patients with nonmalignant diseases, such as bone marrow failure syndromes, hemoglobinopathies, immunodeficiencies, and inborn errors of metabolism, GvHD is not counterbalanced by any positive effect on disease outcome at all. Therefore, regimen-related toxicity and the possibility of severe GvHD are major barriers to allogeneic transplantation for nonmalignant diseases. 13 While these concerns might be less in the case of a matched sibling donor, they are greater with a matched unrelated donor (MUD) and are substantial with a haploidentical donor. Understandably, such concerns often delay this potentially curative therapy while a matched donor is sought.
The most reliable way to prevent acute and chronic GvHD is to completely remove T-lymphocytes from the graft, and several methods of T-cell depletion are available (for review, see Ho and Soiffer 14 ) . However, the incidence of graft failure increases with the extent of in vitro T-cell depletion, and low T-cell numbers in the graft are predictive of graft failure. 15 One way to prevent graft failure despite extensive T-cell depletion, especially in the case of HLA-mismatched transplantation, is to transplant large numbers of CD34 þ stem cells, 16 which can be harvested from donor peripheral blood after mobilization with G-CSF. 17 This megadose concept has been used successfully in MUD and three-loci haploidentical donor transplantation in pediatric 18, 19 and adult 20 patients with malignant diseases.
On the basis of these observations, we initiated a treatment scheme, for MSD, MUD, and haploidenticaldonor allogeneic transplantation for children with nonmalignant diseases. Our strategy was to enhance engraftment by increasing the dose of CD34 þ stem cells while maximally reducing residual T-cell contamination of the graft to prevent GvHD. In order to increase the stem cell dose, we used G-CSF-mobilized peripheral blood stem cells (PBSC) from adult donors for all patients. Extensive T-cell depletion was accomplished by positive selection of CD34 þ stem cells. Here we report the rate of engraftment, incidence of GvHD, immune reconstitution, and the overall survival of 25 children with various nonmalignant diseases who were treated by this method.
Patients and methods
A total of 25 pediatric patients with various nonmalignant diseases were consecutively treated from 1995 to 2001 according to this scheme. At the time of transplantation, the median age of the patients was 4.9 years (range, 0.2-18 years), and the median body weight was 18 kg (range, 4-61 kg). Five of the 25 patients who received mismatched related transplants have been described previously. 21, 22 Five patients had severe aplastic anemia (SAA), two had hemoglobinopathies and one had Diamond-Blackfan anemia. Five patients had immunodeficiency, nine had inborn errors of metabolism, one had polycythemia rubra vera, and two had secondary hemophagocytic lymphohistiocytosis (SHLH). Table 1 lists the details of their diagnoses. The five cases of severe aplastic anemia had been refractory to multiple immunosuppressive therapies. Both patients with SHLH became symptomatic 1 year after successful treatment of a malignant disease (non-Hodgkin's lymphoma and acute myeloid leukemia). They had no response to conventional chemotherapy for lymphohistiocytosis according to the international HLH-94 protocol. 23 The single patient with thalassemia was assigned to class 3 of the Pesaro classification 24 and was pretreated with hydroxyurea, azathioprine, and fludarabine before transplantation at the age of 16.9 years. The single patient with polycythemia vera had been treated with frequent phlebotomy and with interferon alpha for thrombocytosis. No other patients had received pretransplant chemotherapy.
Patients with leukodystrophy were symptomatic (mild ataxia, slight neurocognitive dysfunction, and/or lesions on MR imaging; n ¼ 3) or showed progressive motor dysfunction (n ¼ 1) at the time of transplantation. Patients with osteopetrosis maligna had various degrees of visual impairment (caused by compression of the optic nerve), hepatosplenomegaly, and bone marrow insufficiency. Transplantation was performed in these patients as early as possible (2 months after diagnosis or earlier) in order to prevent further optic nerve compression. The patient with porphyria suffered from severe photodermatitis with disfigurement of his face and fingers.
Donor testing and mobilization and collection of stem cells
The histocompatibility of patient and donor was determined by serological (HLA-A and -B) and high-resolution molecular (HLA-DRB1) typing methods. Four patients had matched related donors, two of which were HLAidentical siblings, and two of which were HLA-identical (because of parental consanguinity) fathers. For 14 patients, unrelated matched donors (n ¼ 9) or donors mismatched at one DRB1 allele (n ¼ 4) and at HLA-A (n ¼ 1) were identified. Seven patients received stem cells from related donors mismatched at 1-3 loci and one patient received a second transplant from a three-loci mismatched haploidentical donor after nonengraftment of unrelated mismatched stem cells (Table 1) . þ stem cells were positively selected by using a modified semiautomated magnetic-activated cell sorting technique (SuperMACS, Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described 25 or by using the automated CLINIMACS device (Miltenyi Biotec). 26 The enriched grafts were analyzed by flow cytometry with a FACSCalibur (Becton-Dickinson, Munich, Germany). Debris, dead cells, cell aggregates, and platelets were excluded by gating on forward and side light scatter and subsequently on CD45 þ , propidium iodide-negative cells. Cell viability was assayed by trypan blue dye exclusion, and the median purity of the CD34 þ stem cells was found to be 97.6%.
Conditioning regimens
The myeloablative conditioning regimens were chosen on the basis of the disease and donor type. Patients with leukodystrophy, Wiskott-Aldrich syndrome, porphyria, polycythemia, and Diamond-Blackfan anemia received oral busulfan (16 mg/kg for age 43 years and 20 mg/kg for age o3 years), cyclophosphamide (200 mg/kg), and rabbit antithymocyte globulin (ATG, 10 mg/kg daily for 3 days). Patients with osteopetrosis, SHLH, or severe combined immunodeficiency (SCID) received cyclophosphamide in combination with oral or intravenous (Busulfex s ) busulfan and thiotepa or fludarabine. Children with severe aplastic anemia received cyclophosphamide (200 mg/ kg) and ATG (30 mg/kg); cyclophosphamide and ATG combined with total lymphoid irradiation (TLI, 8 Gy); or total body irradiation, thiotepa, cyclophosphamide, and ATG. The conditioning regimens are summarized in Table 2 . With the exception of a short course of cyclosporine given to the first two patients, no post transplant immunosuppressive therapy was administered.
Patient assessment and donor lymphocyte infusion
The day of engraftment was defined as the first of 3 consecutive days on which the absolute neutrophil count (ANC) was 40.5 Â 10 9 /l. Peripheral blood chimerism was assessed weekly in peripheral blood samples until day 100 and was then assessed every 3 months as described
þ , and CD56 þ lymphocytes was monitored weekly by FACS analysis until T-cell recovery began and was subsequently assessed every 3 months. Patients were evaluated for GvHD by the Glucksberg criteria. 27 Donor lymphocyte infusions were given only to patients who showed decreasing donor chimerism measured in whole blood by more than 20-30% in two subsequent examinations. Aliquots of the left-over after CD34 þ selection were obtained and frozen from the MUD grafts, whereas mononuclear cells from the related donors were obtained freshly. The first T-cell dose was 2. 
Supportive care
All patients received prophylactic acyclovir, fluconazole, co-trimoxazole (trimethoprim-sulfamethoxazole), and metronidazole. Immunoglobulin was given intravenously each week until day þ 100. G-CSF was administered to most patients. Patients who had IgG antibodies to CMV or whose donor was positive for anti-CMV IgG received highdose acyclovir. PCR screening for CMV was performed weekly. Since 2000, herpes simplex virus, human herpesvirus 6 (HHV6), and Epstein-Barr virus (EBV) were determined additionally. Adenovirus surveillance comprised antigen detection in stools and weekly PCR testing of blood. Additional antiviral treatment was started immediately in the case of positive PCR findings.
Statistical analysis
The probability of survival was estimated by the method of Kaplan and Meier. 28 The association between donor mismatch and the occurrence of GvHD was tested by the K 2 test or Fisher's exact test. The Wilcoxon rank-sum test was used to compare cell doses of patient groups with and without GvHD and to compare T-cell reconstitution in the study group and a control group.
Results

Graft composition
The patients received a median of 12. þ stem cells after a TBI-containing conditioning regimen. Engraftment was not obtained after reconditioning with the anti-CD3 antibody plus steroids 29 followed by transplantation of additional peripheral CD34 þ cells and T-cell-depleted bone marrow from the same donor. This patient then received unmanipulated bone marrow from a closely matched unrelated donor who had been identified in the meantime, but engraftment did not occur.
The two patients with SHLH and WAS engrafted successfully after reconditioning with only steroids and anti-CD3 antibody and reinfusion of purified CD34 þ stem cells from the same donors. Thus, a total of 24 patients (96%) finally engrafted. No association was found between engraftment and the number of antigen mismatches or the number of CD3 þ and CD34 þ cells in the graft. One patient with X-linked ALD and one patient with osteopetrosis experienced autologous reconstitution 1.5 and 1.6 years after transplantation, respectively. The patient with osteopetrosis received another transplant with CD34 þ stem cells from the same donor (3-loci-mismatched father) at the age of 3 years, after reconditioning with TBI (12 Gy), thiotepa (10 mg/kg), and cyclophosphamide (200 mg/kg) and has a stable and complete engraftment with a follow-up of 2 years. The patient with X-ALD did not receive a second transplant because of progressive disease.
GvHD
Of the 24 evaluable patients, 19 (79%) showed no signs of acute GvHD. Three patients (13%) experienced grade I GvHD of the skin and two patients (8%) had grade II GvHD of the skin. No acute GvHD 4grade II occurred. No significant relationship between GvHD and HLA mismatch or number of infused CD34 þ cells was observed. However, the median number of residual T cells in the stem cell graft was significantly higher in the group with GvHD (Table 3) .
Donor lymphocyte infusions and chimerism
Donor T cells were given after transplantation to 11 patients whose weekly assays showed increasing autologous chimerism. These 11 patients received a median of 3 (range, 1À14) donor lymphocyte infusions; six patients received 25 000 CD3 þ T cells/kg, and five patients received larger Tcell doses: 50 000 T cells/kg (two patients); 100 000 T cells/ kg (two patients); and 250 000 T cells/kg (one patient). Of these 11 patients, five achieved complete donor chimerism, five showed either stable or decreasing host chimerism, and one continued to show increasing host chimerism. No GvHD was seen after the donor lymphocyte infusion. As of April 2003, 13 of 21 evaluable patients showed full donor chimerism, seven had mixed chimerism, and one, with X-ALD, had autologous reconstitution. Because of this patient's progressive disease, a second transplant was not considered.
Survival
At the last follow-up (April 2003), 22 of the 25 patients are alive, with a median follow-up of 3.7 years (range, 0.8-7.3 years); 19 were free of disease or had stable disease (Table 3 ). Figure 1a shows estimates of survival and progression-free survival. All patients who received a graft from a matched related donor or a matched or partially matched unrelated donor survived, whereas three of the eight patients who received a graft from a mismatched related donor died (Figure 1b) . The causes of death were nonengraftment (SAA) with subsequent sepsis, relapse of previously treated lymphoma (secondary SHLH), and progressive chronic pulmonary disease (unclassified immunodeficiency).
In all four patients with osteopetrosis, restored osteoclast function resulted in stable hematopoiesis and normalized bone resorption, as shown by radiographs and by calcium/ phosphorus homeostasis. Surprisingly, one patient shown to be blind by visual-evoked-potential dielectroencephalography regained vision.
The patients treated for anemia, immunodeficiency, lymphohistiocytosis, or polycythemia showed normal hematopoiesis and normal numbers of T-, B-and NK cells. In the patient with porphyria, skin lesions resolved, and growth of hair and nails returned to normal. In one patient with X-ALD, the disease stabilized (neurologic dysfunction did not progress). One patient with X-ALD showed autologous reconstitution 1.5 years after transplantation and subsequently experienced severe disease progression. Two other patients with X-ALD and metachromatic leukodystrophy experienced only mild progression (moderate ataxia, reduced vision). Unfortunately, one of the two had EBV-associated lymphoproliferative disease with subsequent transformation to malignant lymphoma. 
Immune reconstitution
A median of 52 days was required to reach a CD3 þ cell count 40.1 Â 10 9 /l and a median of 90 days was required to reach a CD3 þ /CD4 þ T-helper cell count 40.1 Â 10 9 /l. Patients' T-cell counts were completely normal after 1 year. The recovery of CD56 þ NK cells was rapid, and a clear NK-cell peak was observed 1-2 months after transplantation (Figure 2) .
The reconstitution of CD3 þ T cells in this patient group (matched related donors were excluded from this analysis) was compared with that observed in patients with malignant diseases who received purified peripheral-blood CD34 þ progenitors from matched unrelated donors at our institution. This group comprised 31 patients with ALL, AML, or CML with a median age of 10 years. The grafts were similar in purity, median stem cell dose, and number of residual CD3 markedly more rapid in the group with nonmalignant disease, who had significantly higher T-cell counts 1-2 months (P ¼ 0.003), 3-4 months (P ¼ 0.002), 5-6 months (P ¼ 0.02), and 1 year (P ¼ 0.01) after transplantation ( Figure 3 ).
Discussion
Acute and chronic GvHD are major causes of morbidity and mortality, especially when matched unrelated and mismatched related donors are used. [30] [31] [32] Here we have shown that large numbers of highly purified CD34 þ progenitor cells from matched and mismatched related donors and from fully or partially matched unrelated donors can be safely transplanted without significant acute or chronic GvHD. The almost complete absence of GvHD was achieved by using positive selection of CD34 þ cells as an indirect method of T-cell depletion (approximately 5 logs). Patients, who did not show any symptoms of GvHD, received a median number of only 5000 residual T cells/kg, which may be a safe threshold for graft contamination in our setting. This effective in vitro T-cell depletion allowed us to perform the transplants without using pharmacological GvHD prophylaxis. The primary engraftment failure seen in four of the 25 patients was probably related to the high degree of T-cell depletion. 33, 34 However, because of the low toxicity of the preparative regimens, three of the four patients were given successful second transplants, and only one patient, who had SAA and a long history of multiple transfusions, did not experience engraftment. However, it has to be pointed out that five of the 25 patients (20%) needed a second transplant in order to achieve an overall long-term engraftment of 92%, which is similar to other reports. 8, 35 Life-threatening reactivation of viral 5 or fungal 4 infections commonly occurs in patients receiving T-cell-depleted grafts. In our experience, an incidence of lethal infections of 22% was observed in patients with malignant diseases who had received purified CD34 þ progenitors from mismatched related donors. However, none of the patients reported here died of an infectious complication and the incidence of CMV viremia detected by PCR was remarkably low. We ascribe this promising clinical outcome to the rapid immune reconstitution observed in our patients (Figures 2  and 3 ). This observation is consistent with our previous reports that the transplantation of large numbers of highly purified CD34
þ stem cells results in rapid reconstitution of the T-cell system. 22, 36 It is also possible that the thymic epithelium is less damaged in patients with nonmalignant diseases than in patients who have received cancer chemotherapy, and this factor may also contribute to the speed of T-cell reconstitution. In our cohort, only the two patients with secondary hemophagocytic lymphohistiocytosis had received standard chemotherapy before transplantation. An additional explanation might also be the lower age of the patients transplanted for nonmalignant diseases.
Our busulfan-based preparatory regimens were sufficiently ablative to achieve complete donor chimerism in 62% and stable mixed chimerism in 34% of the evaluable patients. One patient with X-linked adrenoleukodystrophy and one with osteopetrosis showed complete regeneration of autologous hematopoiesis 1.5 and 1.6 years after MUD and MMRD transplantation, respectively. However, the patient with osteopetrosis received a successful second transplant 1.5 years after the first transplant, at the age of 3 years (a TBI-containing preparative regimen followed by infusion of highly purified CD34 þ stem cells from the same mismatched related donor). The patient has maintained 100% donor chimerism since then. In order to induce complete or maintain stable mixed donor chimerism, we gave post transplant T-cell addbacks to 11 patients whose serial chimerism assays showed decreasing donor chimerism. Most importantly, no GvHD was induced by these donor lymphocyte infusions, probably because a small yet effective number of T cells was given. Mixed chimerism may be sufficient to cure nonmalignant hematopoietic disease, thus allowing the use of less myeloablative and less toxic preparative regimens. In the case of thalassemia, Time from transplantation Absolute cell count/µl P =0.003 P = 0.002 P = 0.02 Figure 3 Comparison of T-cell reconstitution in patients with nonmalignant and malignant diseases. The reconstitution of CD3 þ T lymphocytes was compared in patients transplanted for nonmalignant diseases (diamonds, matched related donors excluded) vs malignant diseases (circles). All patients received CD34
þ peripheral blood stem cells from matched unrelated donors. The grafts for the two patient groups were similar in purity, median stem cell dose, and number of graft-contaminating CD3 þ T cells.
mixed chimerism is reportedly sufficient to sustain normal hemoglobin production. 37 The same may be true for other diseases.
Allogeneic transplantation was considered to be the only curative approach for our patients' nonmalignant diseases, and all efforts were therefore made to offer this therapy. As transplantation from partially matched unrelated or haploidentical donors is still considered 'experimental' and is rarely used to treat nonmalignant diseases, a number of patients experience disease progression during the prolonged search for a matched donor. These patients either die of their disease or undergo experimental transplantation after their clinical status deteriorates. It is understandable that such patients have a worse clinical outcome than patients who receive transplants earlier in the course of their disease. Two of our three patients who died provide examples of the situation described above. No matching donor could be identified for either patient. One patient's diagnosis (SAA) was made 5 years before MMRD transplantation. During those 5 years, the patient received multiple transfusions, a factor known to be associated with nonengraftment. The other patient had a diagnosis of unclassified immunodeficiency at age 1.5 years, ceased to thrive at age 2 years, and underwent transplantation at age 7 years. The patient had chronic pulmonary disease caused by repeated pulmonary infection. After the CD34 þ cell selection technique became available, the parents opted for a haploidentical-donor transplant. The patient experienced rapid engraftment and was discharged from the hospital. However, his pulmonary function slowly diminished, and he succumbed to chronic lung disease 6 months after transplantation. Both of these patients' transplants were performed in a late stage of their disease. Both might have had a better chance of a favorable outcome had the transplant been performed earlier. However, before the availability of effective indirect T-cell depletion by positive selection, haploidentical grafts were associated with a very high incidence of severe acute and chronic GvHD. For that reason, such transplants had not been considered for these two patients before the availability of the CD34 þ positive selection.
Since our approach is associated with a low rate of transplant-related mortality, we suggest that transplantation should be offered early to those patients with nonmalignant diseases that cannot otherwise be cured and who are at risk of disease progression. The use of matched unrelated and haploidentical donors allows transplantation to be offered at a more favorable time, before disease progression or the worsening of clinical status can diminish the chance of a good outcome. Patients with osteopetrosis offer a good example of the advantage of including mismatched related donors in the donor pool. Some of these patients have significantly impaired vision or even complete blindness at presentation because of bony compression of the optic nerve. 38 Rapid normalization of osteoclast function by allogeneic transplantation can prevent further visual impairment, but the time needed for a MUD donor search would be counterproductive. Most surprisingly, one of our patients who had no measurable visual-evoked potential before transplantion now shows clear visual function 2 years after transplantation. However, a careful risk-benefit analysis must be carried out in cooperation with the patients, their parents, or both to find the best treatment strategy for the underlying disease.
In conclusion, we have demonstrated that the allogeneic transplantation of large numbers of mobilized and highly purified CD34 þ stem cells is an effective therapy for patients with nonmalignant diseases, which allows avoidance of any post transplant immunosuppression and its side effects. In the absence of a matched related donor, transplantation with a matched or partially matched unrelated donor or a mismatched related donor can also be performed with low toxicity, a low incidence of acute and chronic GvHD and a low incidence of infections. It may be possible to further improve the outcome of transplantation of purified peripheral-blood CD34 þ stem cells, for example by adding mesenchymal stem cells to the graft. 39 We believe that timely transplantation with large numbers of purified CD34 þ stem cells is as important as the HLA identity of donor and recipient. Once allogeneic transplantation is identified as the only curative option and is decided to offer a favorable risk-benefit ratio, it should be performed before further progression of the underlying disease.
